Proving the Business Case for the Internet of Things

Rochester University Parkinson’s study uses MC10 wearables

Steve Rogerson
October 15, 2019

Researchers at New York’s University of Rochester are working with Massachusetts wearables company MC10 to gather data on movement disorders such as Huntington’s and Parkinson’s disease.
MC10 created the BioStamp nPoint wearable device, which will be used in the collaboration on advancing methods of assessing central nervous system (CNS) diseases. Researchers will use the wearable to collect continuous data allowing for the creation of algorithms to provide quantitative assessment of disease progression, specifically for movement disorders.
“Movement disorders such as Huntington’s and Parkinson’s disease represent a therapeutic area that lacks objective, quantitative understanding of disease progression, and therapeutic efficacy,” said Arthur Combs, chief medical officer of MC10. “The goals of this research collaboration are to enhance the way we assess people with CNS diseases, improve the way therapies are evaluated and transform the way these patients are managed towards better outcomes.”
MC10 and the University of Rochester have a strong history of collaborations focused mainly on CNS developments, including prior studies on Parkinson’s and Huntington’s disease patients. The upcoming research features more advanced technology and a larger sample size of participants to get a more complete and accurate data set, allowing for robust algorithms and the creation of digital biomarkers.
MC10 hopes these algorithms and the insights gained during the research will be beneficial to many of BioStamp nPoint’s early adopters and improve understanding of movement disorder progression.
“Neurological disorders are the world’s leading source of disability,” said Ray Dorsey, a professor of neurology at University of Rochester. “Unfortunately, drug development for these disorders is littered with failures in part because of shortcomings in traditional rating scales. We need more objective, continuous, sensitive, real-world assessments of how these disorders affect individuals than we can get from subjective rating scales. Wearable sensors, like those from MC10, have the potential to provide us such data. Data that we can use to determine whether new therapies are efficacious.”
The University of Rochester was recently named a Morris K Udall Center of Excellence for Parkinson’s research and awarded a grant to work towards understanding the disease progression of the debilitating disease. Both companies hope the efforts on this collaboration will serve as a basis for Parkinson’s research for years to come.
The University of Rochester is a private university in New York. MC10 is a privately held company focused on improving human health through digital technology. The company combines conformal BioStamp sensors with clinical analytics to unlock insights from physiological data collected from the home or in clinical settings. MC10 is headquartered in Lexington, Massachusetts.